AstraZeneca Earnings Reports

AstraZeneca delivered robust financials in Q3 2025, posting $15.19 billion in revenue and a 64% increase in operating profit. The company continued to benefit from strong demand in oncology, respiratory, and cardiovascular portfolios.

AstraZeneca delivered a strong Q2 2025 with $14.46 billion in revenue and $3.5 billion in net income. The company saw continued growth in its oncology, biopharmaceuticals, and rare disease portfolios, supported by new molecular entities entering Phase III trials.

AstraZeneca posted a strong Q1 2025 with double-digit revenue growth driven by Oncology and BioPharmaceuticals, alongside five positive Phase III study readouts and expanded US manufacturing investments.